Noveome Biotherapeutics Advances to Phase 1-2 Trial for NEC Treatment in Premature Infants

Image: Joshua Taylor/Unsplash

Noveome Biotherapeutics Inc., a clinical-stage company based in the Bridgeside research community near the Southside Works, is making significant strides in the treatment of Necrotizing Enterocolitis (NEC). NEC is a serious intestinal disease affecting 2-5% of premature infants worldwide, leading to symptoms such as poor feeding, vomiting, multi-organ failure, and carries a 25% risk of death even with current treatments. NEC usually develops two to six weeks after birth.

Noveome's innovative approach involves the use of ST266, a promising treatment for NEC. The company recently received FDA approval to proceed with a Phase 1-2 trial. This trial will involve approximately 36 patients divided into two groups: the treatment group receiving ST266 along with the standard of care, and the control group receiving only the standard of care.

For patients in the treatment group, ST266 will be administered daily via IV over a 10-day period. The primary focus of this trial will be to evaluate the safety profile of ST266 and monitor various measurable clinical outcomes.

We extend our best wishes to Noveome Biotherapeutics for the success of their trials and their continued efforts to improve the lives of premature infants affected by NEC.